ArticleBrain research2025
Cannabinoid agonist, WIN 55,212-2, increases in vivo paired-pulse facilitation, long-term potentiation, and Arc expression in the dentate gyrus.
Article in Brain research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
The endogenous cannabinoid system in the hippocampus has the potential to modulate synaptic transmission, including short and long term plasticity, by acting as retrograde messengers. The present study evaluated the effects of WIN 55,212-2, a potent cannabinoid agonist, on paired-pulse facilitation (PPF) and long-term potentiation (LTP) in the dentate gyrus in vivo. WIN 55,212-2 (10 μg/μL; 0.5 μL volume) or vehicle was unilaterally infused into the right dorsal hippocampus of anesthetized rats prior to perforant path stimulation and electrophysiological recordings. Upon completion of physiological recordings, brains were processed for immediate early gene expression (Arc, c-Fos, zif268). WIN 55,212-2 reduced baseline population spike amplitude at high stimulation intensities (500-600 μA), without affecting baseline fEPSP slopes. WIN 55,212-2 also altered fEPSP paired-pulse ratios, suggesting changes in glutamate release probability and GABAergic inhibition. WIN 55,212-2 significantly increased fEPSP slopes following high-frequency stimulation without affecting population spike amplitude, indicating selective enhancement of fEPSPs. Arc expression was significantly elevated in the stimulated dentate gyrus of WIN 55,212-2-treated rats, with no changes in c-Fos or zif268 expression. WIN 55,212-2 may modulate LTP through a combined reduction of glutamate and GABA via feedforward and feedback processes, and may influence baseline and activity-dependent changes via distinct mechanisms. Taken together, these results suggest cannabinoids at high concentration enhance synaptic plasticity mechanisms, which may be important factors driving the effects of cannabinoids on learning and memory.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.